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Abstract
Our study investigated the relationship between MYC alterations and clinicopathological features in gastric cancers. We
evaluated the effect of MYC mRNA expression and its protein immunoreactivity, as well as copy number variation, promoter
DNA methylation, and point mutations, in 125 gastric adenocarcinoma and 67 paried non-neoplastic tissues. We observed
that 77% of the tumors presented MYC immunoreactivity which was significantly associated with increased mRNA
expression (p,0.05). These observations were associated with deeper tumor extension and the presence of metastasis
(p,0.05). MYC protein expression was also more frequently observed in intestinal-type than in diffuse-type tumors
(p,0.001). Additionally, MYC mRNA and protein expression were significantly associated with its copy number (p,0.05). The
gain of MYC copies was associated with late-onset, intestinal-type, advanced tumor stage, and the presence of distant
metastasis (p,0.05). A hypomethylated MYC promoter was detected in 86.4% of tumor samples. MYC hypomethylation was
associated with diffuse-type, advanced tumor stage, deeper tumor extension, and the presence of lymph node metastasis
(p,0.05). Moreover, eighteen tumor samples presented at least one known mutation. The presence of MYC mutations was
associated with diffuse-type tumor (p,0.001). Our results showed that MYC deregulation was mainly associated with poor
prognostic features and also reinforced the presence of different pathways involved in intestinal-type and diffuse-type
gastric carcinogenesis. Thus, our findings suggest that MYC may be a useful marker for clinical stratification and prognosis.
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Introduction
Gastric cancer is the fourth most frequent type of cancer and
remains the second leading cause of cancer-related death
worldwide [1]. This cancer is usually diagnosed at advanced
stages and the single curative therapy available requires surgical
resection [2]. Thus, gastric cancer is a serious public health
problem in the world. An improved understanding of the biology
of this neoplasm is critical and may be useful to guide patient
management, as well as to develop new therapeutic options.
MYC is one of the most studied oncogenes stemming from its
association with a large number of diseases [3]. MYC plays a role
in several fundamental functions of cell biology, including the
regulation of cell growth and proliferation, metabolism, differen-
tiation, apoptosis, and angiogenesis (for review see [4,5]). Hence,
MYC is an integrator of extracellular and intracellular signals, and
its cellular phenotype is dependent on tissue location [6,7]. Not
surprisingly, deregulation of MYC functions contributes to the
tumor phenotype.
MYC deregulation due to gene amplification [8,9], chromo-
somal translocation or insertion [10,11], mutations [12], and
epigenetic modifications [13,14], has been reported in different
types of cancers, especially in gastric cancer. MYC expression is
often elevated or deregulated in human neoplasms [4], and seems
to be at the crossroad of several important pathways and processes
involved in carcinogenesis [15], being a key event in gastric
carcinogenesis [9]. Previously, our group demonstrated that MYC
mRNA expression and copy number increases during the
sequential steps of intestinal-type gastric carcinogenesis in a non-
human primate model [16], suggesting that MYC may be involved
in gastric tumor initiation and progression.
The understanding of MYC biology is of paramount importance
to elucidate its role in the pathogenesis of gastric cancer. Up to
date, there is no study correlating MYC mutation, amplification,
protein/mRNA levels, and methylation in this neoplasia. Here, we
evaluated the relationship between MYC alterations and clinico-
pathological features in gastric cancer. In addition, MYC mRNA
expression and protein immunoreactivity, as well as several
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molecular mechanisms previously related to its deregulation as
copy number variation (CNV), mutation, and DNA methylation,
were analyzed in the same set of gastric cancer samples.
Materials and Methods
Ethics Statement
All samples were derived with written informed consent and
approval from the University Hospital (Bele´m, Para´, Brazil) ethical
review boards (protocol number: 142004).
Clinical Samples
125 gastric adenocarcinoma and 67 corresponding non-
neoplastic gastric tissues (control samples) were obtained surgically
from patients of the Joa˜o de Barros Barreto University Hospital in
Para´ State, Brazil. All subjects were not exposed to either
chemotherapy or radiotherapy before surgery. Gastric tumors
were classified according to Lauren [17] and tumors were staged
using standard criteria by TNM staging [18]. The clinicopatho-
logical features are shown in table 1 and 2.
Dissected tumor and control specimens were quickly frozen in
liquid nitrogen until nucleic acid purification. Another part of the
same tissues was formalin-fixed and paraffin embedded. For the
fluorescent in situ hybridization (FISH) assay, the remaining tumor
sample was disaggregated as previously described [19].
MYC immunoreactivity
Immunohistochemical analyses for MYC protein were per-
formed on 125 formalin-fixed, paraffin-embedded tumor sections.
Immunohistochemical staining was performed according to
Calcagno et al. [10]. Tumor tissue sections (3 or 4 mm-thick)
were deparaffinized in xylene and rehydrated in a graded series of
ethanol. After heat-induced epitope retrieval, the tissue sections
were incubated with primary mouse monoclonal antibody against
MYC (dilution 1:50; sc-40, Santa Cruz Biotechnology, USA and
ZymedH, USA). A universal peroxidase-conjugated secondary
antibody kit (LSAB System, DakoCytomation, USA) was used for
the detection system. We used 3,30-diamino-benzidine/H2O2
(Dakocytomation, Denmark) as the chromogen and hematoxylin
as the counterstain. Any nuclear stain with or without cytoplasmic
staining was considered to be a positive result, irrespective of
intensity. A MYC-positive case was defined as one having 10% or
more tumor cells positive for this protein.
Nucleic acid extraction
The genomic DNA (gDNA) was extracted using the QIAamp
DNA Mini Kit (Qiagen, Germany) following the manufacturer’s
instructions. Total RNA was extracted with Tri-reagentH (Life
Technologies, USA) according to the manufacturer’s protocol.
DNA and RNA concentration and quality were determined using
the NanoDrop spectrophotometer (Kisker, Germany). RNA
integrity was determined by gel electrophoresis (1% agarose gels).
All samples were stored at 280uC until use.
MYC mRNA expression
To quantitate mRNA levels of MYC, total RNA was isolated
from 49 paired normal and tumor tissues using Trizol (Life
Technologies, USA). The RNA was reverse transcribed using the
High-Capacity cDNA Archive kit according to the manufacturer’s
protocol (Life Technologies, USA). Complementary DNA was
then amplified by real-time PCR using the TaqMan probes
purchased as Assays-on-demand Products for Gene Expression
(Life Technologies, USA) on a 7500 Fast Real Time PCR (Life
Technologies, USA). GAPDH gene was selected as an internal
control for RNA input and reverse transcription efficiency. All
real-time reverse transcription quantitative PCR (RT-qPCR) were
performed in triplicate for both target gene (MYC:
Hs00153408_m1) and internal control (GAPDH: NM_002046.3).
Relative quantification (RQ) of the gene expression was
calculated according to Livak and Schmittgen [20]. The corre-
sponding control sample was designated as a calibrator from each
tumor.
MYC copy number
FISH and qPCR were used to evaluate MYC copy number in a
subset of 49 tumors, the same used in the study of the expression.
FISH was performed according to the protocol of Pinkel et al. [21]
with modifications introduced by Calcagno et al. [22]. Cells were
hybridized with Spectrum Orange Probe (LSI Vysis/Abbott, Inc., IL)
for the MYC gene region (8q24.12–q24.13) and nuclei were
counterstained with 49,6-diamidino-2-phenylindole antifade. Fluo-
rescence was detected using an Olympus BX41 fluorescence
microscope (Olympus, Japan) with excitation filters for 49,6-
diamidino-2-phenylindole (260 nm) and rhodamine (570 mn). For
each case, 200 interphase nuclei were analyzed using an ASI
image analysis system (Applied Spectral Imaging, Israel). Positive
MYC gene signals appeared as red spots in nuclei and were scored
using the criteria of Hopman et al. [23]. To avoid misinterpretation
due to technical error, normal lymphocyte nuclei and normal
gastric tissue were used as a control. The FISH results were
presented as the percentage of MYC amplification by a cell, in
which we calculated the percentage of cells showing 3 or more
signals for the MYC probe by cell.
qPCR was performed using quantitative TaqMan CNV assays
(Life Technologies, USA) for the MYC gene (Hs01764918_cn) and
for the internal control RNAse P (#4403326). Multiplex qPCR
reactions were performed in quadruplicate with gDNA according
to the manufacturer’s protocol and cycling conditions in 7500 Fast
Real-Time PCR (Life Technologies, USA). The relative copy
number was estimated for each sample using the Copy Caller
Software V1.0 (Life Technologies, USA). Commercial human
gDNAs (G1521 and G1471; Promega, USA) were used for
calibration.
MYC methylation
The methylation pattern and frequency of the MYC promoter
were evaluated in 125 tumors and 67 matched control samples by
Methyl-specific PCR (MSP) as previously described [24]. gDNA
(2 mg) of all samples was modified by bisulfite treatment,
converting unmethylated cytosines to uracils and leaving methyl-
ated cytosins unchanged [25]. Specific primers for the MYC
promoter were as follows: F59-TAGAATTGGATTGGGG-
TAAA-39 and R59-CCAACCAAAAATCAACATGAAT-39 for
the unmethylated reactions (expected product size of 291 bp); F59-
TAGAATTGGATCGGGGTAAA-39 and R59-CGACC-
GAAAATCAACGCGAAT-39 for the methylated reactions (ex-
pected product size of 290 bp), as previous described [26].
PCR reactions were carried out with 0.1 mmol/L of dNTPs,
2 mmol/L of MgCl2, 0.5 mmol of primers, 1.25 U of Taq DNA
polymerase, and 100 ng of bisulfite-modified DNA. After initial
denaturation for 5 min at 94uC, 40 cycles at 9 4uC for 45 s,
52.4uC for 45 s, and 72uC for 30 s were carried out, followed by a
final extension for 5 min at 72uC. PCR products were directly
loaded onto 3% agarose gels and electrophoresed. The gel was
stained with SYBRH Safe DNA Gel Stain (Life Technolgies, USA)
and directly visualized under UV illumination. As a positive
control of all MSP reactions, a gDNA sample was completely
methylated using CpG Methylase (SssI, New England Biolabs,
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USA) following the manufacturer’s instructions. Furthermore, the
primers for wild-type were used to monitor complete conversion of
DNA obtained in the bisulfite reaction.
Samples were stratified as: 1) hypomethylated samples when
positive amplification product was detected only in the PCR with
specific primers for unmethylated sequences; 2) hypermethylated
samples when positive amplification was detected only in the PCR
with specific primers for methylated sequences; 3) partial
methylated samples when positive amplification was detected in
the PCR with the two primer sets.
MYC Genotyping
The three exons of the MYC gene were selected for mutation
analysis in all 125 gastric cancer samples. The following primers
were designed for PCR amplification and sequencing: exon 1 F59-
TTTATAATGCGAGGGTCTGGA-39 and R59-GCATTC-
GACTCATCTCAGCA-39 (expected product size of 654 bp);
exon 2 F59-CTGCCTCCCGCTTTGTGT-39 and R59-
TTTGATGAAGGTCTCGTCGT-39 (expected product size of
423 bp), F59-TGGGAGGAGACATGGTGAA-39 and R59-
TGCCAATGAAAATGGGAAAG-39 (expected product size of
507 bp); exon 3 F59-TGTCCAGAGACCTTTCTAACGTAT-39
and 59-CCGTAGCTGTTCAAGTTTGTG-39 (expected product
Table 2. Clinicopathological characteristics, MYC mRNA expression, copy number and percentage of amplification in gastric
cancer samples.
Variable (N) RQ Copy number % of amplification (FISH)
Mean±SD p-value g2 OP Mean±SD p-value g2 OP Mean±SD p-value g2 OP
Gender
Female (16) 3.4261.03 0.410 0.015 0.129 4.5061.55 0.402 0.015 0.132 70.6968.03 0.658 0.004 0.072
Male (33) 3.3760.92 4.4861.30 72.7767.81
Onset (years)
#45 (5) 2.6360.82 0.060 0.073 0.472 3.260.45 0.025* 0.103 0.622 60.465.21 ,0.001* 0.257 0.976
.45 (44) 3.4760.93 4.6361.37 73.4266.98
Tumor location
Non-cardia (28) 3.5760.93 0.108 0.055 0.362 4.7561.53 0.102 0.057 0.372 72.5268.36 0.585 0.007 0.084
Cardia (21) 3.1460.93 4.1461.06 71.5267.31
Histologic subtype
Diffuse-type (21) 3.3560.67 0.723 0.003 0.064 3.8160.75 0.009* 0.139 0.762 68.5568.77 0.037* 0.091 0.557
Intestinal-type (28) 3.4161.12 5.0061.52 74.7565.98
Stage
Early (2) 2.0960.14 0.202 0.035 0.245 3.0060.00 0.546 0.008 0.091 54.566.36 0.037* 0.091 0.558
Advanced (47) 3.4460.93 4.5561.37 72.8467.04
Tumor invasion
T1/T2 (11) 2.5560.84 0.006* 0.152 0.801 3.5560.69 0.200 0.035 0.246 60.8266.36 ,0.001* 0.401 1.000
T3/T4 (38) 3.6360.84 4.7661.40 75.3664.53
Lymph node
metastasis
Absent (5) 2.2760.32 0.023* 0.107 0.632 3.2060.45 0.143 0.046 0.308 36.6066.94 0.179 0.039 0.267
Present (44) 3.5160.91 4.6461.37 73.0667.43
Distant metastasis
Absent (23) 2.5060.48 ,0.001* 0.788 1.000 3.6160.66 ,0.001* 0.356 0.999 68.2067.29 0.001* 0.221 0.942
Present (26) 4.1660.41 5.2761.37 75.5466.75
Protein
immunoreactivity
Negative (11) 2.5660.44 0.003* 0.178 0.870 3.2760.47 0.003* 0.177 0.869 65.4568.37 0.009* 0.139 0.759
Positive (38) 3.6360.92 4.8461.35 74.0166.66
DNA methylation
Hypomethylated (42) 3.4060.91 0.802 0.001 0.057 4.4561.37 0.283 0.025 0.186 72.4067.40 0.806 0.001 0.057
Partial methylated (7) 3.3361.24 4.7161.5 70.21610.73
Point mutations
Present (7) 3.7360.79 0.107 0.055 0.363 4.4360.79 0.614 0.006 0.079 72.00610.83 0.216 0.033 0.233
Absent (42) 3.3360.97 4.561.45 72.1167.42
*Differentially expressed between groups, p,0.05.
RQ: relative quantification; N: number of samples; SD: standard deviation; g2: effect size base on Eta Squared; OP: observed power.
doi:10.1371/journal.pone.0064420.t002
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size of 663 bp), 59-TGTCCGTCCAAGCAGAGG-39 and 59-
TGATGAAAACAAACAGGGATG-39 (expected product size of
639 bp).
The PCR reactions were carried out with 0.1 mmol/L of
dNTPs, 2 mmol/L of MgCl2, 0.5 mmol/L of primers, 1 U of Taq
polymerase, and 100 ng of DNA. The PCR conditions were 95uC
for 10 min, followed by 35 cycles of 1 min of denaturation at
95uC, 1 min of annealing temperature (ranging from 59 to 61uC),
and 1 min of extension at 72uC. The amplicons were separated on
a 2% agarose gel stained with SYBRH Safe DNA Gel Stain (Life
Technolgies, USA) and directly visualized under UV illumination.
Amplicons were sequenced using the Sanger method [27].
Direct sequencing was carried out using the Big DyeH Termina-
torv3.1 Cycle Sequencing kit (Life Technologies, USA) and
analyzed on an ABI PRISMH 3130 Genetic Analyzer (Life
Technologies, USA) using Pop 7 polymer. The in silico mutation
search was performed using the Chromas Pro 1.5 (Technelysium
Pty Ltd, Australia). The reference sequence was Gene ID: 4609
(NCBI). Variants with less than 1% minor allele frequency were
reported. Pathogenicity of missense mutations was assessed by in
silico analysis using PolyPhen (http://genetics.bwh.harvard.edu/
pph/) and SIFT (http://sift.jcvi.org).
Statistical analysis
MYC methylation, mutation, or its products’ immunoreactivity
odds ratio (OR) for clinicophatological features was estimated by
logistic regression. The age at gastric tissue sampling was defined
as covariate in the regression model.
The normality of distribution for quantitative variables was
tested by the Shapiro-Wilk’s test. Data that were not normally
distributed were transformed (z-score transformation) into a
normal distribution for analysis. Analysis of MYC mRNA
expression and copy number were performed by the General
Linear Model (GLM) with adjustment for age, which provides the
effect size and observed power (OP) of each analysis. The effect
size for GLM analyses was based on Eta Squared (g2), in which
0.15 and below was determined as a small effect size, 0.16–0.40 as
a medium effect size, and above 0.40 as a large effect size.
The correlation between mRNA expression and copy number
was analyzed by the Pearson test, in which a value of its
correlation coefficient (r) below 0.30 was determined as a weak
correlation, 0.30–0.70 as a medium correlation, and above 0.70 as
a strong correlation.
In all analyses, the confidence interval was 95% and p values less
than 0.05 were considered significant.
Results
MYC amplification is known to be related to high protein/
mRNA expression in gastric carcinogenesis [28], however, to the
best of our knowledge, few studies have been performed to
describe the role of methylation and MYC mutations in this
process. To reach this goal, we analyzed 125 cases in which 68%
were males and 32% were females. The mean age of our sample
set was 62 years (range of 26–89 years). A slightly higher frequency
of intestinal-type (56.8%) and non-cardic (58.4%) tumors were
observed (Table 1 and 2).
MYC nuclear protein was found positive in 76.8% (96/125) of
gastric tumors (Figure 1). MYC protein expression was more
frequently observed in intestinal-type than diffuse-type tumors
(p,0.001, OR=7.856, CI 95%=2.803–22.013) (Table 1). MYC
immunostaining was also associated with late-onset (p = 0.026,
OR=3.276; CI 95%=1.152–9.315), deeper tumor extension
(p=0.045, OR=2.975, CI 95%=1.027–8.623), and the presence
of distant metastasis (p,0.001, OR=17.682, CI 95%=3.914–
79.882) (Table 1). Futhermore, MYC immunoreactivity was
associated with increased mRNA expression (p=0.003,
g2 = 0.178, OP=0.870) and MYC copy number by FISH
(p=0.009, g2 = 0.139, OP= 0.759) and by qPCR (p=0.003,
g2 = 0.177, OP=0.869) (Table 1).
The expression level of MYC mRNA was higher in all tumor
samples than their paired controls (RQ=3.3960.14; range of
1.57–5.18). An increased MYC mRNA expression was associated
with deeper tumor extension (p=0.006, g2 = 0.152, OP=0.801),
presence of lymph node metastasis (p=0.023, g2 = 0.107,
OP=0.632), and distant metastasis (p,0.001, g2 = 0.788,
OP=1) (Table 2). Additionally, the mRNA level was directly
correlated to the MYC copy number (p,0.01; r = 0.716).
Gain of MYC copies was found in all gastric adenocarcinoma
samples by FISH and qPCR assays. By FISH, the mean
percentage of cells presenting MYC amplification was 72.1%
(range of 50 to 83.5% cells with amplification) (Figure 2 A and B).
The mean of MYC copies by qPCR was 4.5 (range 3 to 9 copies)
(Figure 2 C).
FISH and qPCR analyses showed that increased MYC copy
number was associated with late-onset (p,0.001; g2 = 0.257,
OP=0.976; p=0.025; g2 = 0.103, OP= 0.662, respectively ),
intestinal-type cancer (p=0.037; g2 = 0.091, OP= 0.557;
p=0.009; g2 = 0.139, OP= 0.762, respectively), and the presence
of distant metastasis (p=0.001; g2 = 0.221, OP= 0.942; p,0.001;
g2 = 0.356, OP= 0.999, respectively). In addition, MYC amplifi-
cation by FISH was associated with advanced tumor stages
(p=0.037; g2 = 0.091, OP= 0.558), however, only two early
tumors were analyzed in this subset of samples (Table 2).
All gastric cancer samples presented positive amplification with
an unmethylated primer set. Interestingly, 86.4% of cancer
samples were hypomethylated. On the other hand, the presence
of unmethylated sequences at the MYC promoter was observed in
28.4% of control samples (partial methylated samples), suggesting
the loss of methylation in these samples (Figure 3). The primers’s
specificity and MSP results were confirmed using the bisulfite
sequencing PCR (BSP) approach [29] in which we randomly
selected five hypomethylated samples; five hypermethylated
samples and five partial methylated samples (data not shown).
MYC hypomethylation was more frequently observed in the
diffuse-type as compared to the intestinal-type gastric cancer
(p=0.007; OR=8.554; 95% CI=01.798–40.695, using diffuse-
type as reference group). In addition, MYC hypomethylation was
associated with advanced tumor stages (p=0.033; OR=6.602;
95% CI= 1.162–37.501), deeper tumor extension (p=0.022;
OR=4.752; 95% CI= 1.257–17.965), and the presence of lymph
node metastasis (p=0.032; OR=5.12; 95% CI= 1.149–22.814)
(Table 1).
With regards to gene sequencing, no novel mutation was
detected in gastric tumors. Thirteen (10.4%) tumor samples
presented at least one known mutation, with variants on less than
1% minor allele frequency. In total, 18 mutations were identified,
with 4 samples exhibiting co-occurring mutations. In exon 1, five
with GG and four with CG at rs117856857; one with GG at
rs73707292; and four with CT at rs4645949. In exon 2,
concerning missense mutations, two tumors harbored a mutation
at codon 47 resulting in a change from tyrosine to histidine
(rs114570780; SIFT prediction =deleterious; PolyPhen predic-
tion= probably damaging), and two at codon 72 resulting in a
change from proline to serine (rs28933407; SIFT prediction= -
tolerated; PolyPhen prediction= probably damaging). All tumor
with a mutation in exon 2 presented one or two known mutation
in exon 1. Exon 2 mutations were only detected in diffuse-type
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tumors in advanced stage. No mutation was identified in exon 3.
The presence of known MYC mutations was associated with
diffuse-type tumors (p=0.004, OR=21.717, 95% CI= 2.678–
176.111; using diffuse-type as reference group) and the presence of
distant metastasis (p=0.032, OR=4.492, 95% CI= 1.141–
17.679).
Discussion
The MYC protein has an effect on about 15% of the genes in
the human genome [30]. Thus, MYC deregulation may result in
alterations in different biological pathways involved in cancer
initiation and progression [5]. However, up to date, the
relationship between MYC alterations and clinicopathological
parameters has not been well understood. Our samples presented
a male-female ratio of 2:1 and the majority of the patients were
Figure 1. MYC protein expression. A) intestinal-type gastric cancer without MYC immunoreactivity (4006); B) intestinal-type gastric cancer
presenting MYC immunoreactivity (4006); C) diffuse-type gastric cancer without MYC immunoreactivity (4006); D) diffuse-type gastric cancer
presenting MYC immunoreactivity (4006).
doi:10.1371/journal.pone.0064420.g001
Figure 2. MYC amplification in gastric cancer. A) interphase nuclei
presenting MYC amplification (red) in intestinal-type gastric cancer; B)
interphase nuclei presenting MYC amplification (red) in diffuse-type
gastric cancer; C) MYC copy number distribution by qPCR in intestinal-
type and diffuse-type tumors.
doi:10.1371/journal.pone.0064420.g002
Figure 3. Methylation analysis of the MYC promoter showing
methylated and unmethylated bands. Sample 1 presented partial
methylation. Samples 2, 3 and 4 presented a hypomethylated promoter.
C-: blank; C+: positive control, gDNA sample completely methylated; U:
unmethylated; M: methylated: MW: molecular weight marker; bp: base
pairs.
doi:10.1371/journal.pone.0064420.g003
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older than fifty-five. Moreover, the intestinal-type gastric cancer
was more frequent than the diffuse-type and tumors were more
frequent in non-cardia. These epidemiological data are in
accordance with previous studies [28,31–33].
Chromosomal translocations in the MYC locus is very commun
in haematopoietic cancers. However, in solid human tumours like
gastric cancer, MYC alterations are commonly due to gene
amplification [34]. Furthermore,MYC is recognized to be the most
frequently amplified protein-coding gene across all cancer types
[35]. In the present study, we observed three or more MYC gene
copies in all gastric tumors studied, corroborating with previous
studies in primary gastric tumors of individuals from our
population [10,28,36–39], as well as from Eastern Asia and
Europe [40–42]. Also, MYC amplification was observed in plasma
[43] and in gastric cancer cell lines established in our group [44–
47]. Additionally, our group had observed that clonal high
amplification of MYC is less frequent in diffuse-type than in
intestinal-type primary gastric cancer [10,22,28], and this was
reinforced by this study.
MYC overexpression is described as ranging from 15.6% to
100% in primary gastric cancers [9]. In vitro studies with knocked-
down MYC expression in gastric cancer cell lines demonstrated
the crucial role of MYC expression in gastric tumor cell growth,
survival, and the maintenance of tumor cell parameters that may
contribute to malignant potential [48]. Moreover, Mehndiratta et
al., [49] showed a significant decrease (40%) in MYC expression of
both mRNA and protein and its downstream targets using siRNA.
In the present study, 76.8% of gastric tumors showed MYC
immunoreactivity and all tumors, intestinal and diffuse type,
presented increased mRNA expression compared to their paired
controls. Furthermore, we observed that MYC immunoreactivity
and increased mRNA expression were associated with deeper
tumor extension and presence of metastasis. These findings suggest
that MYC has a role in the tumor invasiveness, metastasis, and
thus aggressiveness, corroborating a previous study [37]. Although
some analyses presented a small effect size, these findings are also
in agreement with a previous study of our group in non-human
primates, in which we demonstrated a continuous increase of MYC
mRNA expression and copy number during the sequential steps of
intestinal-type gastric carcinogenesis in N-methyl-nitrosourea
(MNU)-treated non-human primates [16]. On the other hand,
any association between MYC and histological grade, tumor
location, lymph node metastasis, or pathological stage was
detected in a gastric cancer study developed in a Chinese
population [50], reinforcing that the ethnicity of the afflicted
population may lead to biologically and clinically gastric cancer
subsets [51].
Although, gene amplification is not necessarily associated or
required for its overexpression, our study shows that MYC
immunoreactivity, MYC mRNA levels, and copy number were
directly correlated.
DNA methylation is a potent mechanism of transcriptional
repression. Proper genomic methylation-patterns become pro-
foundly altered in cancer cells: both gains (hypermethylation) and
losses (hypomethylation) of methylated sites have been observed
[52,53]. Hypomethylation at specific promoters can activate the
aberrant expression of oncogenes and loss of imprinting in some
loci [44]. So far, few studies discussed the relationship between the
methylation pattern of MYC and its effect on gene expression and
on carcinogenic processes. MYC hypomethylation was previously
associated with the oncogenic progression and metastasis induc-
tion in a rat model of liver cancer [54] and in human colorectal
cancer samples [55]. In addition, MYC hypomethylation was also
associated with MYC expression in gastric tumors [26,56–58] and
cell lines [48]. However, we were unable to observe a significant
association between MYC hypomethylation and its expression in
our samples. Among other factors, this lack of association may be
due to the presence of MYC amplification in all tumors with
hypomethylated promoters (86.4% of samples) and thus, masking
the possible effect of this epigenetic modification on MYC
transcriptional regulation.
Suzuki et al. [59] previously showed that a high level of
hypomethylation was an indicator of poor prognosis in both
gastric and colon cancer, and epigenetic alterations were age
dependent, occuring before genetic alterations. In the present
study, some controls already presented unmethylated sequences in
the MYC promoter. In addition, we demonstrated that MYC
hypomethylation was associated with a more aggressive phenotype
(tumor aggressiveness, presence of lymphnode metastasis, and
histological types of cancer). These findings suggest that MYC
demethylation may be accumulated during tumor progression and
this could be a common event in gastric carinogenesis [60,61],
since this mechanism has been observed for other genes in several
tumor types [62,63]. As already proposed for DNA hypermethyla-
tion [64], the promoter hypomethylation may be used as a new
generation of biomarkers and holds diagnostic and prognostic
promise for clinicians.
To the best of our knowledge, MYC gene exons have never been
completely sequenced in human gastric tumors. Here, we
sequenced the three exons of MYC: exon 1 is a non-coding
protein, exons 2 and 3 are protein-coding [for review see
(Pelengaris & Khan, 2003)]. We did not find any new mutation,
however, we observed that 4 tumors presented missense mutations
(rs114570780 and rs28933407) on exon 2. These mutations were
in an evolutionary conserved sequence of MYC: the transactivation
domain [4,65]. In addition, both identified mutations were
considered as probably damaging according to the PolyPhen
software. The change of proline to serine at codon 72 was also
previously reported as a pathogenic variant in the NCBI dbSNP
database (http://omim.org/). Thus, both mutations at exon 2 may
affect MYC activity in gastric tumors. In addition, the presence of
MYC mutations was associated with distant metastasis. However,
further investigations are necessary to clarify if MYC mutations
have a role in the metastatic process.
According to Laure´n classification, gastric adenocarcinoma is
classified mainly into intestinal and diffuse types [17]. Intestinal-
type gastric cancer progresses through a number of sequential
steps, beginning with atrophic gastritis followed by intestinal
metaplasia, intraepitelial neoplasia, and carcinoma [66]. On the
other hand, the diffuse-type generally does not evolve from
precancerous lesions [67,68]. In the present study, we observed
that the intestinal-type presented more frequent MYC immuno-
reactivity, as well as a higher number of MYC copies than diffuse-
type tumors, which corroborates with previous studies of our
group [10,22,28,38]. In addition, MYC hypomethylation and point
mutations were more frequently observed in diffuse-type as
compared to intestinal-type tumors. Thus, our findings support
that these two histological subtypes follow different genetic
pathways and may be two distinct entities [67].
In conclusion, our data suggest that MYC overexpression and
promoter hypomethylation may have a role in the gastric
carcinogenesis process. MYC deregulation was associated mainly
to poor prognostic features. Our results also reinforce the presence
of different pathways involved in intestinal-type and diffuse-type
gastric carcinogenesis. Thus, our findings suggest that MYC may
be a useful marker for clinical stratification and prognosis.
MYC and Gastric Cancer
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